The Estrogen shortage of 2026: what’s actually happening, and what to do about it.
The estrogen shortage of 2026: what's actually happening, and what to do about it.
If your pharmacy keeps telling you your estrogen patch is on backorder, you're not imagining it. Here's the real story — and your real options for staying on hormone therapy that actually works.
For the first time in 20+ years, women in midlife are getting honest conversations about hormone therapy. The market wasn't ready for it. The shortage is the result.
What's actually happening
In November 2025, the FDA removed the black-box warning that had sat on systemic estrogen products since 2003 — a warning based largely on the original Women's Health Initiative data, which has since been substantially re-interpreted. By February 2026, prescription estrogen use among women aged 45-54 had nearly doubled compared to 2023.
Manufacturing capacity didn't double. The result has been rolling shortages, particularly of transdermal estradiol patches (Climara, Vivelle-Dot, Dotti, Lyllana, and most generics). The American Society of Health-System Pharmacists currently lists multiple estrogen products as on shortage. Major manufacturers like Amneal Pharmaceuticals have publicly confirmed they're working to scale production but expect intermittent supply issues to continue through late 2026.
What this means in practice: women who have finally found a hormone protocol that works are walking into pharmacies and being told their refill isn't available. No clear timeline. No alternative offered. Just "check back next week."
Why this matters
For most patients on hormone therapy, going off and on isn't dangerous — but it does mean symptoms come back. Hot flashes return. Sleep disrupts. Mood shifts. The patient who was finally feeling like themselves is suddenly back to where they started. That's the real cost of the shortage.
Why patches specifically are hardest hit
Transdermal patches are often the preferred delivery method for systemic estrogen for one important reason: they bypass the liver. That matters because oral estrogen undergoes "first-pass metabolism" through the liver, which slightly increases clotting protein production. For most women this is acceptable, but for women with cardiovascular risk factors or a history of blood clots, transdermal delivery is meaningfully safer.
So when patches go on backorder, switching to an oral pill isn't a clean substitute for everyone. It depends on individual risk factors — which is exactly why a real clinical conversation matters more than ever during a shortage.
Your actual options right now
If you're on hormone therapy and your patch isn't available, you have more options than your pharmacist may have time to explain. Here's the clinical landscape:
1. Switch to a different transdermal form
The active ingredient in patches — estradiol — is the same molecule used in transdermal gels, sprays, and creams. These deliver estrogen the same way (through the skin, bypassing the liver) but use different delivery vehicles. Estradiol gel (Estrogel, Divigel) and estradiol spray (Evamist) are both manufactured forms with their own supply chains and aren't currently on shortage at the same severity as patches. For many patients, this is the closest substitute.
2. Switch to oral estradiol
If you don't have cardiovascular risk factors or a personal history of blood clots, oral estradiol is a reasonable option. It's effective for symptom management and has been extensively studied. The increased clotting risk compared to transdermal is real but small for most healthy women. This is a clinical conversation, not a one-size-fits-all answer.
3. Compounded bioidentical estradiol
Compounding pharmacies can prepare bioidentical estradiol creams, troches, and other custom formulations. This is where it matters that your provider has experience working with compounding pharmacies — not all do. Compounded estradiol is not FDA-approved (compounded medications never are by definition), but PCAB-accredited compounding pharmacies follow rigorous quality standards, and bioidentical compounded preparations have decades of clinical use behind them.
The American College of Obstetricians and Gynecologists has noted that compounded bioidentical hormones are appropriate for patients who cannot tolerate or access FDA-approved alternatives. The shortage has made that "cannot access" condition far more common.
4. Vaginal estrogen for genitourinary symptoms only
If your primary symptom concern is vaginal dryness, painful intercourse, or recurrent UTIs (the symptoms collectively called genitourinary syndrome of menopause), local vaginal estrogen — creams, rings, and tablets — is a different supply chain entirely and isn't experiencing the same shortage. Vaginal estrogen also addresses these symptoms more effectively than systemic therapy alone.
5. Don't substitute without a provider conversation
The biggest mistake patients make during a shortage is silently going off therapy and waiting for their patch to come back. That's understandable — pharmacies are busy, providers are hard to reach, and "wait it out" feels like the path of least resistance. But the shortage is unlikely to fully resolve until late 2026, which is too long to be off therapy if your symptoms were significantly affecting your quality of life.
Why compounding pharmacy access matters more than ever
At Defiance Health, our hormone therapy program is built on the WorldLink ABHRT methodology — an evidence-based approach to bioidentical hormone replacement that emphasizes individualized dosing, comprehensive lab work, and ongoing protocol adjustment. The methodology has always emphasized using injectable and topical bioidentical hormones as first-line therapy rather than defaulting to one specific patch brand.
That clinical approach is now turning into a practical advantage. Because we work with PCAB-accredited compounding pharmacies as a routine part of our protocols, our patients have access to compounded bioidentical estradiol creams and other formulations when manufacturer supply is constrained. We're not scrambling to find alternatives — we already had them.
This isn't a knock on women who want manufactured FDA-approved patches. Those products are excellent when available. But the supply landscape has changed, and women whose providers don't have established compounding pharmacy relationships are facing real disruptions to their care.
What we tell our patients during this shortage
Don't go off therapy without talking to a provider. The shortage is real, but it doesn't mean your only options are wait-and-see. Comprehensive hormone protocols have always included multiple delivery methods — what's changed is that the workaround conversations that used to feel optional are now central to care.
For Denver and SLV women: what to do this week
If your patch is on backorder right now and you're not sure what to do, here's the practical playbook:
- Call your prescribing provider's office. Don't wait for your symptoms to come back. Most clinicians are hearing from patients about this issue daily and have established backup protocols.
- Ask specifically about transdermal alternatives. Gel, spray, or compounded cream are the closest substitutes to patches for delivery method. If your provider's response is "we'll just switch you to a pill," that's a clinical decision worth discussing — not a default.
- If you don't have a hormone-specialty provider, find one. The Menopause Society maintains a directory of certified providers. ABHRT-trained providers (like our WorldLink-certified team) typically have established compounding pharmacy relationships.
- Don't try to substitute over-the-counter. There's no over-the-counter version of bioidentical estradiol. Anti-histamines, supplements, and "natural alternatives" don't replace systemic estrogen for symptoms driven by estrogen deficiency.
The bigger picture
The shortage will eventually resolve as manufacturers scale production. But the conversation about hormone therapy that's been happening for the past 18 months — the one that brought patients back to clinics asking about HRT for the first time in 20 years — isn't going anywhere. The black-box removal validated what the clinical evidence had been showing for over a decade: properly dosed, properly monitored hormone therapy in the right patients is one of the most effective interventions in midlife women's health.
Defiance Health has been built around that clinical reality. Comprehensive labs that go beyond the standard panel. Real provider time at intake — 75 minutes, not seven. Established relationships with compounding pharmacies that give us flexibility most clinics don't have. And both Jessica Lara, PA-C (WorldLink ABHRT certified) and Randi Asbell, APRN (currently completing her advanced certification) trained in the same methodology.
If you're struggling with the shortage, or if you've been considering hormone therapy and the current news has surfaced more questions than answers, we'd be happy to start the conversation.
Talk to a hormone-specialty provider
Whether you're dealing with the shortage or considering hormone therapy for the first time, our comprehensive intake gives you a real clinical conversation — and the lab work to back it up.
Learn About Our Hormone TherapyThis article is reviewed by Jessica Lara, PA-C, founder and clinical director of Defiance Health. Defiance Health operates clinics in Centennial, Colorado (Denver metro) and Alamosa, Colorado, with telehealth follow-ups available for established patients in CO, AZ, CA, and WA.